Israel Patent System

Mobileye Global Inc. (Jerusalem; founded 1999 by Prof. Amnon Shashua and Ziv Aviram at the Hebrew University of Jerusalem; Intel acquisition July 2017 for $15.3B — at the time the largest acquisition of an Israeli company; partial IPO Nasdaq October 2022 at ~$17B valuation): Mobileye is the world's leading supplier of advanced driver assistance systems (ADAS) chips and computer vision software for automotive applications. Key patents: (1) EyeQ chip series patents — the EyeQ1 (launched 2007) through EyeQ6 Ultra system-on-chip patents cover computer vision processing architectures for real-time camera-based object detection (vehicles, pedestrians, cyclists, lane markings, traffic signs) at automotive-grade power envelopes; (2) camera-only ADAS architecture: Mobileye built early ADAS around monocular camera + CNN-based computer vision, filing patents on monocular depth estimation, free-space mapping, pedestrian detection algorithms; (3) RSS (Responsibility-Sensitive Safety) mathematical model patents: a formal mathematical framework for autonomous vehicle behavioral safety decision-making; (4) True Redundancy architecture: camera-only path and radar-only path computed independently and cross-checked for Level 4 autonomous driving; chip architecture + software pipeline patents; (5) REM (Road Experience Management) HD mapping: crowdsourced HD map service aggregating data from vehicles with EyeQ chips; cloud processing + map update distribution patents. Mobileye files primarily via USPTO + EPO. Mobileye competes with NVIDIA DRIVE, Qualcomm Snapdragon Ride, Tesla FSD Chip, and Bosch's camera systems in autonomous driving silicon.

Check Point Software Technologies Ltd. (Tel Aviv; founded 1993 by Gil Shwed, Marius Nacht, Shlomo Kramer — all Technion Computer Science alumni and Unit 8200 veterans; Nasdaq CHKP; ~$20–22B market cap): Check Point is the world's original commercial network firewall company — Gil Shwed invented stateful packet inspection in 1993 and filed the foundational firewall patent (US 5,606,668, issued 1997; Israeli priority date 1994). Stateful inspection tracks the state of active network connections rather than inspecting each packet in isolation, and became the foundational architecture for essentially all modern commercial firewalls. Key patent domains: (1) Stateful packet inspection (US 5,606,668 and related) — core firewall technology; (2) Threat emulation and SandBlast: CPU-level threat emulation analyzing code behavior at CPU instruction level before malware can evade OS-level detection; (3) CloudGuard multi-cloud security posture management; (4) ThreatCloud intelligence network: real-time threat intelligence sharing across Check Point's global install base. CyberArk Software (Newton MA + Petah Tikva; NASDAQ CYBR; ~$15–18B; founded 1999 Udi Mokady + Alon Cohen): privileged access management (PAM) — securing privileged credentials (admin accounts, service accounts, API keys); credential vault encryption, session monitoring, just-in-time privilege escalation, detection of privilege abuse patents. Wiz (New York + Tel Aviv; Google acquisition $23B 2025 — largest cybersecurity acquisition ever; founded 2020 by Assaf Rappaport + 3 co-founders, former Microsoft Cloud Security executives who sold Adallom to Microsoft $320M 2015): agentless cloud security posture management (CSPM); cloud vulnerability graph scanning patents. Unit 8200 alumni ecosystem: Palo Alto Networks (Nir Zuk, also Check Point alum), SentinelOne, Armis (IoT/OT security), Claroty (industrial cybersecurity), Cato Networks (Shlomo Kramer — who also co-founded Check Point). Israel = world's second-largest cybersecurity cluster after Silicon Valley, generating ~$8–11B annual cyber exports.

Israel has one of the world's most sophisticated defense technology industries. Key entities: Rafael Advanced Defense Systems (Haifa; state-owned; ~$3–4B annual revenue): Iron Dome air defense system (co-developed with Israel Aerospace Industries; fully operational 2011; US co-production via Raytheon; >$3B US Congressional appropriations 2011–2022); the Iron Dome detection-to-interception sequence (Tamir interceptor missiles + ELM-2084 MMR radar; track-while-scan radar, threat assessment algorithm, intercept point computation, two-stage Tamir guidance) involves multiple patents on active phased-array radar signal processing, mobile air defense command-and-control software, proximity fuze technology. Rafael also develops: Spike anti-tank guided missile (ATGM) family (Spike SR/MR/LR/ER/NLOS — electro-optical/imaging infrared seeker patents; fiber-optic guidance link for man-in-the-loop guidance; widely exported worldwide); Trophy active protection system (APS) for main battle tanks (millimeter-wave radar detection of incoming threats, countermeasure projectile patents); Spice precision guidance kit (GPS/IIR seeker glide bomb guidance patents). Elbit Systems (Haifa; Nasdaq ESLT; ~$5–6B revenue; world's largest non-state defense electronics company): DASH helmet-mounted display systems for F-16 pilots; SkyGuardian UAV; Torch-X C4I situational awareness; digital battle management systems. Israel Aerospace Industries (IAI; state-owned): HERON tactical UAV, BARAK air defense, Arrow anti-ballistic missile (co-developed with Boeing + Raytheon for exo-atmospheric interception), HAROP loitering munition patents. Cellebrite (Petah Tikva; NASDAQ CLBT): UFED mobile digital forensics patents for law enforcement (data extraction protocols across iOS, Android, hundreds of device models). Defense patents: some classified under Israeli secrecy orders; many filed at ILPO and/or USPTO with security review.

Teva Pharmaceutical Industries Ltd. (Petah Tikva; NYSE and TASE; world's largest generic pharmaceutical company by revenue ~$15–16B; founded 1901): Teva's IP strategy represents a complex dual approach — as the world's largest generic drug manufacturer, Teva has aggressively challenged innovator pharmaceutical patents through Paragraph IV ANDA filings (Hatch-Waxman), while holding a branded pharmaceutical patent portfolio: (1) Copaxone (glatiramer acetate) for multiple sclerosis: Copaxone was Teva's most important branded product (~$4B peak revenue). Original compound patents expired. Teva's secondary patent strategy covered manufacturing process improvements, the '40 mg three-times-weekly' dosing regimen, and specific polymer characteristics. Mylan and Sandoz filed Paragraph IV ANDA challenges; US Federal Circuit invalidated several key secondary Copaxone patents 2015–2017; generics launched; Copaxone revenue collapsed from ~$4B peak to under $1B — the Copaxone saga is a canonical example of pharmaceutical patent evergreening and its limits under vigorous generic challenge; (2) Austedo (deutetrabenazine) for Huntington's disease chorea and tardive dyskinesia: deuterium-incorporated small molecule (deuterium substitution slows CYP2D6 metabolism); deuterium-substituted pharmaceutical patents are a contested patenting strategy; (3) Ajovy (fremanezumab): anti-CGRP monoclonal antibody for migraine prevention. Copaxone was developed at the Weizmann Institute of Science (Yeda Research + Development Co.); the IP path from academic research at Weizmann → Teva licensing → commercial product → patent litigation is itself a significant case study in Israeli tech transfer. Israeli pharmaceutical patents: fully patentable under Israeli law (no § 3(d) equivalent, no Indian/Colombian restrictions). Israeli data exclusivity: 5 years for NCEs (Ministry of Health, separate from patent term).

Waze Mobile Ltd. (Tel Aviv; founded 2008; Google acquisition July 2013 for approximately $966M): Waze is the world's largest community-based GPS navigation application. Key patents: real-time traffic speed estimation from probe vehicle GPS data (crowd-sourced floating car data), road closure and hazard reporting algorithm, dynamic route recalculation with user-contributed data, social navigation features. After the Google acquisition, Waze patent activity was consolidated under Google's patent program. The Waze acquisition demonstrated global appetite for Israeli navigation/location technology and set the stage for subsequent large Israeli tech exits. OrCam Technologies (Jerusalem; founded 2010 by Amnon Shashua and Ziv Aviram — the same founders as Mobileye; private company valued ~$1B+): OrCam MyEye wearable device — a small camera that clips to glasses and provides audio feedback to people with visual impairments or reading difficulties (reads text, identifies faces, recognizes products and money); wearable real-time text recognition, optical character recognition with minimal latency, face recognition + user-defined alert systems, gesture-based activation interface patents. Distinctive in that Shashua/Aviram built both Mobileye (automotive computer vision) and OrCam (assistive computer vision) on related underlying computer vision technology. AudioCodes (Lod; NASDAQ AUDC): voice-over-IP technology patents, Session Border Controller patents; Radcom (NASDAQ RDCM): 5G network assurance patents; Wix (Tel Aviv; NYSE WIX; ~$6–8B market cap): website builder platform patents (drag-and-drop editor, headless CMS, website rendering infrastructure); Check Point, Imperva (WAF/DLP application security), Radware (DDoS mitigation), and dozens of other Israeli security + cloud companies hold USPTO + EPO patent portfolios managed from Israeli HQs.

Israel's Patents Law § 7 (as amended in 1995) provides a 12-month own-disclosure grace period: disclosures made by the applicant (or someone who derived the information from the applicant) within 12 months before the filing date do not count as prior art for novelty purposes. This is narrower than it initially appears — the key limitation is that it applies only to the applicant's OWN disclosures, not to third-party independent disclosures. If a third party independently discovers and publishes the same invention before your Israeli filing date, that publication IS prior art for your Israeli application regardless of the § 7 grace period. The US AIA § 102(b)(1)(A) grace period is similar in structure — it also protects the applicant's own disclosures within 12 months. The EPC countries (Germany, France, Netherlands, Sweden, Czech Republic, etc.) have NO comparable own-disclosure grace period — any public disclosure before the EPC filing date destroys European patent rights. Practical implications for Israeli patent strategy: (1) file before any public disclosure for EPC country coverage regardless; (2) for Israeli national rights, the 12-month window after the inventor's own disclosure is available but narrow and risky if competitors might independently develop the same technology; (3) do not disclose without a patent application filed because third-party independent disclosures have no grace period protection in Israel. The absolute best practice: file the patent application (or at minimum a PCT application with Israeli priority) before making any public disclosure about the invention.

Intel's $15.3 billion acquisition of Mobileye in March 2017 (completed August 2017) was at the time the largest acquisition of an Israeli company ever. The deal reflected Intel's strategic bet that autonomous vehicles would become a major computing platform and that Mobileye's dominant market position in ADAS chips and computer vision would provide access to that market. Several IP-centric factors drove the valuation: (1) Dominant ADAS market share: at acquisition, Mobileye's EyeQ chips were installed in the majority of production vehicles worldwide with camera-based ADAS features (automatic emergency braking, lane departure warning, forward collision warning); Mobileye had supply relationships with 27 automakers and 450+ car models; (2) Deep computer vision algorithm IP: Mobileye had spent nearly two decades developing proprietary automotive environment algorithms; real-world automotive datasets, training pipelines, and object recognition accuracy built into the EyeQ chip represented IP moats that could not easily be replicated; (3) Patent portfolio for autonomous driving: Mobileye held hundreds of patents covering camera-only object detection, monocular depth estimation, and the EyeQ architecture; (4) Automotive customer relationships: automotive-grade semiconductor supply involves multi-year design-in cycles, crash safety data validation, and regulatory type approval — durable moats difficult for new entrants to penetrate; (5) Intel's competitive positioning: Intel was falling behind NVIDIA (which had pivoted to autonomous driving via NVIDIA DRIVE platform with a massive GPU compute advantage) and needed an automotive semiconductor beachhead. The subsequent Mobileye IPO in October 2022 at ~$17B valuation (Intel retained ~88% post-IPO) reflected continued autonomous driving investment appetite.

Israel's cybersecurity industry is the world's second-largest after Silicon Valley, generating approximately $8–11B in annual cyber product and service exports. The industry's genesis is closely tied to Unit 8200 — the IDF's Sigint/cyber intelligence unit (comparable to the US NSA). Unit 8200 alumni who transition to civilian careers bring: (1) Deep offensive and defensive cyber skills — Unit 8200 trains operators in offensive cyber capabilities, vulnerability research, malware development, network penetration, and intelligence analysis; (2) Strong technical networks — Unit 8200 alumni know each other and co-found companies together; the alumni network is extremely tight-knit; (3) Real-world adversarial experience — dealing with actual nation-state cyber threats provides intuition about attack vectors that academic training alone does not provide. Famous Unit 8200 alumni companies include: Check Point (Gil Shwed, Marius Nacht, Shlomo Kramer), CyberArk (Udi Mokady, Alon Cohen), Wiz (Assaf Rappaport, Yinon Costica, Roy Reznik, Ami Luttwak — Google acquisition $23B 2025), SentinelOne (Tomer Weingarten, Almog Cohen), Palo Alto Networks (Nir Zuk — also Check Point alum), Armis, Claroty, Cato Networks (Shlomo Kramer — who also co-founded Check Point), and many others. Patent activity from this ecosystem is primarily directed to USPTO and EPO, not ILPO — Israeli cybersecurity companies immediately file in the US because that is the primary commercial market. IP in cybersecurity is often trade-secret-primary: publishing a vulnerability detection algorithm trains adversaries to evade it, so the most sensitive detection logic is not patented at all. Patented IP tends to cover infrastructure (authentication protocols, session management, data governance) rather than detection algorithms.

Teva's Copaxone (glatiramer acetate) franchise is one of the most extensively analyzed examples of secondary pharmaceutical patent strategy and its limits: (1) Background: glatiramer acetate is a random copolymer of four amino acids that reduces relapse frequency in relapsing-remitting MS. It was developed at the Weizmann Institute and licensed to Teva via Yeda Research and Development. The original compound patents expired in the early 2000s. Teva maintained market exclusivity through manufacturing know-how (complex polymer structure made bioequivalent generics technically difficult), regulatory strategy (FDA required complex immunological comparability data), and secondary patents; (2) Secondary patent strategy: when original compound patents expired, Teva filed patents on: manufacturing process improvements; the '40 mg three-times-weekly' dosing regimen (claiming the new schedule was more convenient and patentable over original 20 mg daily dosing); and specific polymer characteristics; (3) Generic challenges: Mylan Pharmaceuticals and Sandoz filed Paragraph IV ANDA challenges asserting Teva's secondary Copaxone patents were invalid or not infringed. US Federal Circuit decisions in 2015–2017 invalidated or found unenforceable key secondary Copaxone patents. Generic glatiramer acetate launched; Teva's Copaxone revenue fell from ~$4B peak to under $1B; (4) Lessons: secondary pharmaceutical patents (formulation, dosing, process) can extend effective market exclusivity but are vulnerable to invalidity challenges; the Copaxone case reinforced that evergreening strategies face significant litigation risk when secondary patents are not clearly inventive; glatiramer acetate's complex polymer structure ultimately provided more durable market exclusivity than any individual patent; (5) Israeli context: Copaxone originated at the Weizmann Institute via Yeda TTO, illustrating Israel's world-class university technology transfer pipeline for pharmaceutical innovation.

The 'Start-Up Nation' model describes Israel's disproportionate concentration of high-technology start-ups relative to its population of ~9 million. As of 2023–2024, Israel has approximately 6,000–8,000 active tech start-ups and more companies listed on Nasdaq than any country except the US and China. Patent implications: (1) US-centric filing: Israeli start-ups file at USPTO as their primary patent market almost universally. ILPO national patent is of secondary commercial importance because the US is the dominant exit market — most Israeli start-ups either IPO on Nasdaq or exit via acquisition by a US tech company. IP protection that matters for a US exit is US IP protection; (2) Rapid PCT filings with Israeli priority: many Israeli start-ups file a provisional application at USPTO (or an Israeli priority application at ILPO) and then file PCT within 12 months, entering US, European, and sometimes Asian national phases at 30 months. The PCT phase provides time to raise Series A or B funding before incurring national phase costs; (3) Build-to-exit IP strategy: Israeli start-ups often pursue IP strategy with a specific acquirer profile in mind — what IP would Google, Microsoft, Intel, Cisco, or Palo Alto Networks find most valuable? This shapes claim drafting and prosecution strategy; (4) Trade secret primary in cybersecurity: the most sensitive detection and offensive techniques are maintained as trade secrets rather than patented, because publishing the claim publishes the technique; (5) Government support: Israel Innovation Authority (IIA) provides matching grants for R&D including patent application cost support, reducing the financial barrier to patent filing for early-stage companies. IIA grants require IP to remain based in Israel (royalties paid back to IIA from commercialization revenue); (6) University tech transfer: Yissum (Hebrew University — Mobileye), Yeda (Weizmann — Copaxone, multiple pharma), Technion T3 (Check Point founders' academic home) are among the world's most productive university technology transfer offices by commercial impact.